Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Examining New Breast Cancer Therapy
Clinical Breakthroughs

Examining New Breast Cancer Therapy

By Sarah PlumridgeMar 3, 2016
Share
Facebook Twitter Email
massimo
Massimo Cristofanilli, MD, professor of Medicine in the Division of Hematology/Oncology, was first author on a clinical trial that found a combination of drugs might be an effective treatment for patients with advanced breast cancer.

A combination of the drugs palbociclib and fulvestrant provides an effective and well-tolerated therapy for patients with recurrent metastatic breast cancer who are resistant to endocrine therapy, according to a new Northwestern Medicine study.

This phase III clinical trial, published in Lancet Oncology, followed up an initial analysis and focused on the various aspects of endocrine resistance in hormone receptor-positive metastatic breast cancer, which relies on estrogen to grow and progress. The paper also included clinical and safety endpoints.

Palbociclib stops the cell cycle and prevents cancer cells from dividing, and fulvestrant binds to estrogen receptors blocking the growth of cancer cells. While both have been shown to be effective treatments in postmenopausal metastatic breast cancer, this study was the first time the combination of drugs had been tested in premenopausal women.

“We learned the drug continues to be effective and saw significant progression for survival,” said first author Massimo Cristofanilli, MD, professor of Medicine in the Division of Hematology/Oncology. Dr. Cristofanilli is also the associate director for Precision Medicine and Translational Research at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. “Palbociclib represents an alternative to chemotherapy for a patient that may have developed endocrine resistance, and it is certainly less toxic.”

The trial was performed in 144 centers in 17 countries from 2013 to 2014. Eligible patients had hormone receptor-positive metastatic breast cancer. Patients were also women over 18 years old and of any menopausal status.

The 521 enrolled patients were randomly assigned to receive palbociclib and fulvestrant or a placebo and fulvestrant. A significant improvement in either progression-free survival or the time from randomization to disease progression (or death) was demonstrated in patients receiving the combination of palbociclib and fulvestrant over just fulvestrant.

The scientists also measured patients’ levels of hormone-receptor expression, PIK3CA mutational status (a common gene mutation in estrogen resistant breast cancer) and other clinical measures. They found the efficacy of palbociclib was shown to be independent of the degree of hormone resistance. This finding means that palbociclib could be used as a therapeutic for patients regardless of the level of endocrine sensitivity and resistance and PIK3CA mutation status.

The scientists are continuing to study overall survival in patients.

“We are looking at other molecular correlations in the blood, including estrogen receptor mutations, and we are interested in the long-term advantages and survival benefit,” Dr. Cristofanilli said.

Pfizer sponsored the study, and AstraZeneca provided fulvestrant.

Cancer Research
Share. Facebook Twitter Email

Related Posts

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

Comments are closed.

Latest News

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.